Northwest Biotherapeutics (Northwest Biotherapeutics) Debt-to-Equity : -0.69 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Debt-to-Equity?

Northwest Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $20.79 Mil. Northwest Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $24.77 Mil. Northwest Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-65.77 Mil. Northwest Biotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Northwest Biotherapeutics's Debt-to-Equity or its related term are showing as below:

NWBO' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.68 Med: -0.51 Max: -0.06
Current: -0.69

During the past 13 years, the highest Debt-to-Equity Ratio of Northwest Biotherapeutics was -0.06. The lowest was -4.68. And the median was -0.51.

NWBO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs NWBO: -0.69

Northwest Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Northwest Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Debt-to-Equity Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.40

-0.06

-0.31

-0.21

-0.69

Northwest Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.21	-0.56	-0.50	-0.58	-0.69

Competitive Comparison of Northwest Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Northwest Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Debt-to-Equity falls into.

Northwest Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Northwest Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(20.794	+	24.766)	/	-65.773
	=	-0.69

Northwest Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(20.794	+	24.766)	/	-65.773
	=	-0.69

Northwest Biotherapeutics (OTCPK:NWBO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Northwest Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Executives

Navid Malik	director	1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch	officer: Chief Technical Officer	22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton	director, officer: Chief Scientific Officer	22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman	officer: See Remarks	C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers	director, 10 percent owner, officer: President and CEO	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski	director	C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis	officer: See Remarks	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer	director	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp	10 percent owner	27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund	10 percent owner	C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc.	10 percent owner	7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer	director	10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr.	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814